Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
Suspect bacterial meningitis in acute febrile encephalopathy with meningeal signs or unexplained sepsis; do not delay therapy for diagnostics in unstable patients. Check glucose and electrolytes, obtain blood cultures, and perform head CT prior to LP only with focal deficits, seizures, immunocompromise, or altered consciousness suggesting mass effect. CSF analysis (cell count, glucose, protein, Gram stain, PCR) directs pathogen‑specific management.
Treatment Strategy & Disposition
Give empiric, age‑adjusted IV antibiotics and dexamethasone when pneumococcal disease is suspected, ideally before or with the first antibiotic dose. Tailor coverage as culture/PCR results return, manage complications (seizures, raised ICP), and implement droplet precautions for meningococcal disease. Admit to ICU when neurologic monitoring, airway protection, or vasopressors are required; arrange prophylaxis for close contacts when indicated.
Epidemiology / Risk Factors
- Immunosuppression, devices; recent hospitalization
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Inflammation/infection | Leukocytosis/leukopenia | |
| Lactate | Hypoperfusion | Elevated | Trend |
| Blood cultures | Pathogen ID | Positive/negative | Before antibiotics if feasible |
Common Empiric Regimens (Adult)
| Population | Regimen | Additions |
|---|---|---|
| 18–50 years | Ceftriaxone + vancomycin | — |
| >50 or immunocompromised | Ceftriaxone + vancomycin + ampicillin | Listeria coverage |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Ceftriaxone + vancomycin | β-lactam + glycopeptide | Hours | Empiric adult therapy | Allergy; nephrotoxicity (vanc) |
| Ampicillin (add >50 or immunocompromised) | β-lactam | Hours | Listeria coverage | Allergy |
| Dexamethasone | Glucocorticoid | Hours | Adjunct for S. pneumoniae | Hyperglycemia |
Prognosis / Complications
- Depends on host and source control; sepsis/organ failure risk
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Airborne/contact precautions for suspected meningococcal disease until ruled out. Consider acyclovir if encephalitis on differential.
References
Meet MDSteps: Smarter USMLE® Prep
MDSteps streamlines your study with an adaptive QBank (19,000+ high-yield MCQs across all 3 Steps), full CCS case simulations for Step 3 with live vitals and timed orders, and an exam-readiness dashboard that turns practice into insight. Build mastery by system and discipline, auto-create missed-item decks (Anki-exportable), and keep momentum with pacing guidance, trend lines, and suggested next sessions—so every block moves you closer to test-day confidence.
Compared with staples like UWorld and AMBOSS, MDSteps aims to give you the best of both worlds: exam-style practice that adapts to you, plus real-time analytics and a full CCS runner—all in one place. If you want targeted, exam-relevant reps with feedback that actually changes how you study, MDSteps is built for you.
Eplore MDSteps